SinusitisNCT04841343
Triamcinolone Packing Following Endoscopic Sinus Surgery
An observational study of Sinusitis, run by University of California, Los Angeles at 1 site in United States.
Trial summary
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sinusitis
- What is being tested?
- Triamcinolone
- How many people
- 22 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jan 2021to 30 Sep 2022
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients over age 18 who have bilateral chronic sinusitis who have failed previous medical therapy and will undergo endoscopic sinus surgery
Who may be able to join
- aged 18 and older
- diagnosis of chronic rhinosinusitis based on the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis definition
- failed a trial of previous medical therapy
- have bilateral sinus disease on CT imaging
- will undergo bilateral endoscopic sinus surgery.
Who cannot join
- unable to give informed consent
- not a candidate for endoscopic sinus surgery
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized Controlled Trial of Triamcinolone Impregnated Hemostatic Bioabsorbable Middle Meatus Nasal Packing Following Endoscopic Sinus Surgery
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers compared to no spacers, with a follow up 2013 systematic review finding no difference between the use of absorbable and non-absorbable spacers. This review, however, noted that steroidal spacers may reduce middle meatus scarring and adhesions. More recent data has shown the effectiveness of steroid releasing middle meatus implants in preventing middle turbinate lateralization, reducing synechiae formation, and reducing revision surgery. However, these stents are costly, and may result in excess crusting postoperatively, which limits their use in some settings. Another study investigated the use of steroid-impregnated absorbable packing materials, and demonstrated the safety and utility of this method of middle meatus packing. However, a limitation to this study was overall low enrollment with only 19 total patients enrolled.
The purpose of this project is to add to the existing body of evidence regarding middle meatus spacers, by studying the impact of steroid impregnated, bioabsorbable hemostatic packing (Hemopore®, Stryker) on postoperative visualization and scar formation.
Read the detailed description
Introduction
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers compared to no spacers, with a follow up 2013 systematic review finding no difference between the use of absorbable and non-absorbable spacers. This review, however, noted that steroidal spacers may reduce middle meatus scarring and adhesions. More recent data has shown the effectiveness of steroid releasing middle meatus implants in preventing middle turbinate lateralization, reducing synechiae formation, and reducing revision surgery. However, these stents are costly, and may result in excess crusting postoperatively, which limits their use in some settings. Another study investigated the use of steroid-impregnated absorbable packing materials, and demonstrated the safety and utility of this method of middle meatus packing. However, a limitation to this study was overall low enrollment with only 19 total patients enrolled.
The purpose of this project is to add to the existing body of evidence regarding middle meatus spacers, by studying the impact of steroid impregnated, bioabsorbable hemostatic packing (Hemopore®, Stryker) on postoperative visualization and scar formation.
Research Design The proposed study will be a randomized controlled trial comparing steroid impregnated bioabsorbable and dissolvable nasal packing to non-steroid impregnated packing. Potential subjects will be adults, aged 18 and older, with a diagnosis of chronic rhinosinusitis based on the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis definition, who have failed a trial of previous medical therapy, have bilateral sinus disease on CT imaging, and will undergo bilateral endoscopic sinus surgery. If the patient chooses to proceed with surgery for their medically refractory chronic rhinosinusitis they will be introduced to the research proposal and if willing to participate, the informed consent process will take place, during their preoperative visit. On the day of surgery the patient's right and left sinuses will be randomized to either steroid or no steroid middle meatus packing. At the end of the surgical procedure, the attending surgeon will soak the Hemopore in either 5 cc Duobiotic saline irrigation (bacitracin 50,000 units, polymyxin B 500,000 units in 0.9% sodium chloride 500mL) or 1 ml of triamcinolone 40 mg/ml (Kenalog-40, Bristol-Myers Squibb) mixed with 5 cc Duobiotic saline irrigation and label them 1 (no steroid) and 2 (steroid). The fellow or resident surgeon will then insert the packing into the middle meatus, with the steroid packing going into the side randomized for steroid, and the non-steroid packing going into the other side. A password protected data file will be maintained in UCLA Box, accessible to the investigators, where the side of placement of the packing will be recorded. Postoperative visits will be scheduled at the usual time points: 7-10 days, 24-30 days, and 2-3 months post-op. Nasal endoscopy will be performed at each visit, as a standard post op procedure. Video recording of the endoscopy will be saved for review at the conclusion of the study for determination of the patency of the postop cavity using the Lund-Kennedy endoscopic scoring system (LKES) and the perioperative sinus endoscopy (POSE) score . Symptom scores will also be collected and reviewed, as it is current practice for patients to respond to the sinonasal outcome test-22 (SNOT-22) at preop and postop visits. LKES and POSE scores will be recorded in a password protected file in UCLA Box that is separate from the file containing the side of steroid packing.
The investigators plan to enroll 50 consecutive patients in this study, over the course of about 4-6 months. At the end of the study period, the endoscopy scores (LKES and POSE) will be compared between the steroid and non-steroid sides. Each patient will serve as his/her own control. Statistical analysis will be performed using paired t tests for continuous variables and chi-square tests for categorical variables. A p value < 0.05 will be considered statistically significant.
- Conditions
- Sinusitis
- Being tested
- Triamcinolone
- Medical subject headings
- Sinusitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TriamcinoloneDrug
Triamcinolone in sinus
What is being measured
The primary outcome is the main question the study is designed to answer.
Lund Kennedy Endoscopy score
Assessment of inflammation, crusting, polyps, edema in sinus; Scale from 0 to 2, with higher scores meaning worse outcome
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2021
- Study start29 Jan 2021
- Primary completion30 Sep 2021
- Study completion30 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for SinusitisStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 22 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marilene Wang, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04841343
- Sponsor's protocol ID
- 20-002080
- Status last verified
- Jul 2023
- First submitted
- 7 Apr 2021
- Last updated
- 1 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhao X, Grewal A, Briel M, Lee JM. A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery. Int Forum Allergy Rhinol. 2013 Nov;3(11):896-904. doi: 10.1002/alr.21201. Epub 2013 Jul 24.
PubMed 23894058Cote DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. 2010 Jun;120(6):1269-73. doi: 10.1002/lary.20905.
PubMed 20513050
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial of Triamcinolone Impregnated Hemostatic Bioabsorbable Middle Meatus Nasal Packing Following Endoscopic Sinus Surgery
- ClinicalTrials.gov ID
- NCT04841343
- Acronym / sponsor ID
- 20-002080
- Conditions
- Sinusitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 29 Jan 2021 (actual)
- Primary completion
- 30 Sep 2021 (actual)
- Study completion
- 30 Sep 2022 (actual)
- First posted
- 12 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers compared to no spacers, with a follow up 2013 systematic review finding no difference between the use of absorbable and non-absorbable spacers. This review, however, noted that steroidal spacers may reduce middle meatus scarring and adhesions. More recent data has shown the effectiveness of steroid releasing middle meatus implants in preventing middle turbinate lateralization, reducing synechiae formation, and reducing revision surgery. However, these stents are costly, and may result in excess crusting postoperatively, which limits their use in some settings. Another study investigated the use of steroid-impregnated absorbable packing materials, and demonstrated the safety and utility of this method of middle meatus packing. However, a limitation to this study was overall low enrollment with only 19 total patients enrolled.
The purpose of this project is to add to the existing body of evidence regarding middle meatus spacers, by studying the impact of steroid impregnated, bioabsorbable hemostatic packing (Hemopore®, Stryker) on postoperative visualization and scar formation.
Detailed description
Introduction
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers compared to no spacers, with a follow up 2013 systematic review finding no difference between the use of absorbable and non-absorbable spacers. This review, however, noted that steroidal spacers may reduce middle meatus scarring and adhesions. More recent data has shown the effectiveness of steroid releasing middle meatus implants in preventing middle turbinate lateralization, reducing synechiae formation, and reducing revision surgery. However, these stents are costly, and may result in excess crusting postoperatively, which limits their use in some settings. Another study investigated the use of steroid-impregnated absorbable packing materials, and demonstrated the safety and utility of this method of middle meatus packing. However, a limitation to this study was overall low enrollment with only 19 total patients enrolled.
The purpose of this project is to add to the existing body of evidence regarding middle meatus spacers, by studying the impact of steroid impregnated, bioabsorbable hemostatic packing (Hemopore®, Stryker) on postoperative visualization and scar formation.
Research Design The proposed study will be a randomized controlled trial comparing steroid impregnated bioabsorbable and dissolvable nasal packing to non-steroid impregnated packing. Potential subjects will be adults, aged 18 and older, with a diagnosis of chronic rhinosinusitis based on the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis definition, who have failed a trial of previous medical therapy, have bilateral sinus disease on CT imaging, and will undergo bilateral endoscopic sinus surgery. If the patient chooses to proceed with surgery for their medically refractory chronic rhinosinusitis they will be introduced to the research proposal and if willing to participate, the informed consent process will take place, during their preoperative visit. On the day of surgery the patient's right and left sinuses will be randomized to either steroid or no steroid middle meatus packing. At the end of the surgical procedure, the attending surgeon will soak the Hemopore in either 5 cc Duobiotic saline irrigation (bacitracin 50,000 units, polymyxin B 500,000 units in 0.9% sodium chloride 500mL) or 1 ml of triamcinolone 40 mg/ml (Kenalog-40, Bristol-Myers Squibb) mixed with 5 cc Duobiotic saline irrigation and label them 1 (no steroid) and 2 (steroid). The fellow or resident surgeon will then insert the packing into the middle meatus, with the steroid packing going into the side randomized for steroid, and the non-steroid packing going into the other side. A password protected data file will be maintained in UCLA Box, accessible to the investigators, where the side of placement of the packing will be recorded. Postoperative visits will be scheduled at the usual time points: 7-10 days, 24-30 days, and 2-3 months post-op. Nasal endoscopy will be performed at each visit, as a standard post op procedure. Video recording of the endoscopy will be saved for review at the conclusion of the study for determination of the patency of the postop cavity using the Lund-Kennedy endoscopic scoring system (LKES) and the perioperative sinus endoscopy (POSE) score . Symptom scores will also be collected and reviewed, as it is current practice for patients to respond to the sinonasal outcome test-22 (SNOT-22) at preop and postop visits. LKES and POSE scores will be recorded in a password protected file in UCLA Box that is separate from the file containing the side of steroid packing.
The investigators plan to enroll 50 consecutive patients in this study, over the course of about 4-6 months. At the end of the study period, the endoscopy scores (LKES and POSE) will be compared between the steroid and non-steroid sides. Each patient will serve as his/her own control. Statistical analysis will be performed using paired t tests for continuous variables and chi-square tests for categorical variables. A p value < 0.05 will be considered statistically significant.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients over age 18 who have bilateral chronic sinusitis who have failed previous medical therapy and will undergo endoscopic sinus surgery
Key inclusion criteria (5 listed)
- aged 18 and older
- diagnosis of chronic rhinosinusitis based on the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis definition
- failed a trial of previous medical therapy
- have bilateral sinus disease on CT imaging
- will undergo bilateral endoscopic sinus surgery.
Key exclusion criteria (2 listed)
- unable to give informed consent
- not a candidate for endoscopic sinus surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TriamcinoloneTriamcinolone in sinus | Drug | – |
Primary outcome
Lund Kennedy Endoscopy score
Time frame: 1 week
Assessment of inflammation, crusting, polyps, edema in sinus; Scale from 0 to 2, with higher scores meaning worse outcome
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2023.
- Background: PubMed 23894058Zhao X, Grewal A, Briel M, Lee JM. A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery. Int Forum Allergy Rhinol. 2013 Nov;3(11):896-904. doi: 10.1002/alr.21201. Epub 2013 Jul 24.
- Results publication: PubMed 20513050Cote DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. 2010 Jun;120(6):1269-73. doi: 10.1002/lary.20905.
- Individual participant dataSharing planned: No
Related trials for Sinusitis
Not yet recruiting
FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps
Chronic Sinusitis, Nasal Polyposis
RecruitingPhase 4
Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)
ACUTE SINUSITIS, Sinusitis
Not yet recruiting
Effect of Probiotic Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis
Sinusitis Chronic, Postoperative Care
Active, not recruitingObservational study
Endotypic Stability in CRS
Chronic Sinusitis
RecruitingPhase 4
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
Chronic Sinusitis, Nasal Polyps
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sinusitis, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lund Kennedy Endoscopy score (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04841343, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2023; AzTrials last refreshed its copy on 29 Oct 2026.